Back to Search Start Over

Supplementary Figures from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers

Details

Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....1bc4ca9a28232b9ab6dbed65a27587fa